Selumetinib, in combination with some existing cancer drugs (eg, docetaxel, erlotinib, cetuximab), is being/has been investigated in clinical trials for treating KRAS-MT solid tumors including non-small-cell lung cancer (NSCLC) [40, 41] and CRC [42]. The gene discussed is KRAS; the disease is cancer.